Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment

Hamza N Gokozan; Madhu M Ouseph; Jose V Scarpa Carniello; Koen Van Besien; Sanjay S Patel

doi:10.1111/cyt.13160

Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment

Cytopathology. 2022 Nov;33(6):757-759. doi: 10.1111/cyt.13160. Epub 2022 Jul 1.

Authors

Hamza N Gokozan¹, Madhu M Ouseph², Jose V Scarpa Carniello¹, Koen Van Besien³, Sanjay S Patel²

Affiliations

¹ Division of Cytopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.
² Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.
³ Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York, USA.

PMID: 35713946
DOI: 10.1111/cyt.13160

Abstract

The authors discuss a case of CD19-negative diffuse large B-cell lymphoma with central nervous system relapse following CD19-directed CAR T-cell treatment. Absence of CD19 expression by the tumour cells presented a challenge for flow cytometry evaluation.

Keywords: CAR T-cell Therapy; CNS Relapse; Cytopathology; Diffuse Large B-cell Lymphoma.

MeSH terms

Antigens, CD19
Central Nervous System / pathology
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Large B-Cell, Diffuse* / therapy
T-Lymphocytes / pathology

Substances

Antigens, CD19